Shenzhen Kangtai Biological Products (300601.SZ): Four-strain influenza virus split vaccines obtained drug registration certificate.

18:28 20/03/2026

Kangtai Biotech (300601.SZ) announced that the company's quadrivalent influenza virus split vaccine has received the "Drug Registration Certificate" issued by the National Medical Products Administration. The quadrivalent influenza virus split vaccine is suitable for individuals aged 3 and above, can stimulate the body to produce immunity against influenza viruses, and is used to prevent seasonal influenza caused by vaccine-related strains.

Shenzhen Kangtai Biological Products (300601.SZ) announced that the company's quadrivalent influenza split virus vaccine has received the "Drug Registration Certificate" issued by the National Medical Products Administration today. The quadrivalent influenza split virus vaccine is suitable for individuals aged 3 and above, and can stimulate the body to produce immunity against influenza viruses, used to prevent epidemic influenza caused by vaccine-related strains.

Dingdang Health (09886) releases annual performance, shareholders' net loss narrowed by 87.0% to 49.018 million yuan.

CIMC ENRIC(03899): CIMC Enric's net profit attributable to shareholders for the year 2025 is approximately 193 million yuan, a decrease of 30.73% year-on-year.

MULTIFIELD INTL (00898) issues profit warning, expecting a comprehensive pre-tax loss of approximately HK$650 million to HK$730 million for the year 2025.

Dingdang Health (09886) releases annual performance, shareholders' net loss narrowed by 87.0% to 49.018 million yuan.

CIMC ENRIC(03899): CIMC Enric's net profit attributable to shareholders for the year 2025 is approximately 193 million yuan, a decrease of 30.73% year-on-year.

MULTIFIELD INTL (00898) issues profit warning, expecting a comprehensive pre-tax loss of approximately HK$650 million to HK$730 million for the year 2025.